Phase 1 Neuroendocrine Carcinomas Clinical Trials
3 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–3 of 3 trials
Recruiting
Phase 1
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Neuroendocrine TumorsCarcinoma, NeuroendocrineNeuroendocrine Carcinomas+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT06041516
Recruiting
Phase 1Phase 2
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Small Cell Lung CancerNeuroendocrine CarcinomasSolid Tumor Show to Express DLL3
IDEAYA Biosciences208 enrolled39 locationsNCT07174583
Recruiting
Phase 1Phase 2
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Small Cell Lung Cancer ( SCLC )Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Neuroendocrine Carcinomas (NEC)+3 more
Phanes Therapeutics203 enrolled12 locationsNCT05652686